Bloomberg Law
Feb. 17, 2022, 10:35 AMUpdated: Feb. 17, 2022, 8:35 PM

Drug Price Reporting Rules Foiled by Supply Chain Loopholes (1)

Sara Hansard
Sara Hansard

U.S. transparency rules for drug and health costs are being stymied by interlocking business deals between insurers, pharmacy liaisons, and other companies, including some that are overseas.

Those are observations gleaned from industry comments about a multi-agency rule (RIN 0938 AU66) designed to give employers and insurers a window into how the care they’re paying for is priced. Entities at every stage of the supply chain say they need more information on what the other companies in the system are paying.

Getting that information may be difficult. The Federal Trade Commission deadlocked 2-2 Thursday on a proposal to ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.